Reviewed by Nabus Research · last reviewed 2026-07-12 · about our review process

○ Human lifespan evidence: none

Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

What it is

Class: Botanical parent compound (thin standalone data)

Also known as: Astragalus membranaceus, cycloastragenol, astragaloside IV

Relationship to telomere biology: Astragalus membranaceus and its purified saponin cycloastragenol are the botanical parent material from which TA-65 is derived. Cycloastragenol is the compound with reported telomerase-activating activity, but standalone human telomere data on raw astragalus/cycloastragenol (outside the branded TA-65 formulation) are thin.

Regulatory status

Sold as a botanical dietary supplement; not an approved drug and not approved for any anti-aging indication. Human telomere evidence outside the TA-65 formulation is limited to preclinical and marketing-level claims.

Mechanism

Cycloastragenol is the putative active telomerase activator in astragalus; most of the human evidence is really the TA-65 program (see the TA-65 page). Raw-compound human telomere data are thin. See /telomerase-tert-terc.

Animal lifespan evidence

Animal lifespan evidence: none in this dataset

No animal lifespan study for raw astragalus or generic cycloastragenol is included in this dataset.

This is separate from human lifespan evidence, which is none for every intervention on this site. A mouse lifespan result is not a human lifespan result, and a telomere change is not a lifespan result in either species.

Evidence — Preclinical / thin human verify: verified at review level, not primary source

Species / population	Cell and animal studies of cycloastragenol; human telomere data are essentially the branded TA-65 trials rather than raw astragalus.
Exposure, route, schedule	Cycloastragenol / astragalus extracts (variable, non-standardised outside TA-65).
Comparator / duration	Mostly preclinical; no standalone powered human telomere RCT of the raw compound.
Endpoint / numeric result	In-vitro telomerase activation and preclinical signals; standalone human telomere-length outcomes are not established outside TA-65.
What it did NOT establish	No qualifying standalone human RCT for a telomere or aging outcome; no lifespan evidence. The activation-cancer-risk question applies.

Negative or null findings

Human telomere evidence for raw astragalus/cycloastragenol is thin and largely subsumed by the commercial TA-65 program.
No lifespan or clinical-outcome data; telomerase activation carries an unresolved cancer-risk question.

Related mechanisms

telomerase-tert-terc

Astragalus / cycloastragenol (raw)